^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    datelliptium (NSC311152)

    i
    Other names: NSC311152, NSC 311152, SR 95156B, NSC 626718X, SR95156A, SR 95156A
    Associations

    News

    Trials
    Company:
    Sanofi
    Drug class:
    BRAF inhibitor, MEK inhibitor, mTOR inhibitor, Topoisomerase II inhibitor, PI3K inhibitor, AKT inhibitor, ERK inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity. (PubMed, Cancers (Basel))
    Finally, datelliptium inhibited approximately 75% of MTC xenograft growth with minimal systemic toxicity. In conclusion, datelliptium exerts its antitumor activity against MTC cells by reducing the EMT program, migratory ability, and self-renewal capacity of TT cells, thus preventing invasive and metastatic behavior of MTC.
    Journal
    |
    RET (Ret Proto-Oncogene) • VIM (Vimentin)
    |
    VIM expression
    |
    datelliptium (NSC311152)